Mycosis fungoides primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cutaneous T cell lymphoma}} | {{Cutaneous T cell lymphoma}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{S.G.}} | ||
==Overview== | ==Overview== | ||
There are no established measures for the | There are no established measures for the secondary prevention of mycosis fungoides but recommended effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease. every 4–6 weeks | ||
==Secondary Prevention== | |||
effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease. every 4–6 weeks. | |||
==References== | ==References== | ||
| Line 14: | Line 14: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: (name of the system)]] | |||
Revision as of 20:35, 19 December 2018
|
Cutaneous T cell lymphoma Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
There are no established measures for the secondary prevention of mycosis fungoides but recommended effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease. every 4–6 weeks
Secondary Prevention
effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease. every 4–6 weeks.